US › Healthcare

Sera Prognostics Inc (SERA)

US · Healthcare · Medical Devices

$2.06+1.48%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$30,000

Revenue YoY

+76.5%

Net profit

$-9.1M

EPS

$-0.18

EPS estimate

$-0.14

Net margin

-30,463.3%

EPS came in at -0.18 against a street estimate of -0.14 — a miss of 28.6%.

Key statistics

Market cap

$80.5M

Forward P/E

0.0

P/B

1.38

Book value

$1.51

EPS (TTM)

$-0.68

52-week high

$3.95

52-week low

$1.56

50-day MA

$2.04

200-day MA

$2.24

Beta

1.06

Analyst view

Analysts rate Sera Prognostics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $5.50.

Shareholding

Insiders

12.13%

Institutions

50.20%

Largest institutional holders

Fund	Stake
Baker Bros Advisors LP	13.94%
Whetstone Capital Advisors, LLC	8.38%
Aberdeen Group PLC	6.98%
Vivo Capital, LLC	4.18%
Vanguard Capital Management, LLC	3.29%
CapTrust Financial Advisors	1.36%
Geode Capital Management, LLC	0.88%
BlackRock Inc	0.56%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sera Prognostics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.